Remove Disease Remove Research Remove Small Molecule
article thumbnail

Researchers devise new way to target and correct disease-related proteins

Broad Institute

Related groups Xavier lab Over the past two decades, large genetic studies have linked tens of thousands of DNA variants to thousands of human traits and diseases. Yet, correcting the effects of those variants to treat disease has been hampered in part by the lack of precise molecular tools to do so.

Disease 135
article thumbnail

Small Molecule of the Year – 2022

Drug Hunter

. #2: MRTX1133 (Mirati Therapeutics/Array BioPharma, 21%) The 2nd place runner-up is MRTX1133 , the non-covalent KRAS(G12D) inhibitor and is the first reported inhibitor specific for G12D, which makes up as much as 33% of all KRAS mutations and carries a 2 to 3-fold higher disease burden than G12C. LP0200 has completed a Ph.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Interactions of small molecule inhibitors with secreted phospholipase A2: A review of the structural data

Chemical Biology and Drug Design

sPLA 2 inhibitors have been developed for the treatment of inflammatory and other conditions such as cardiovascular disease, arteriosclerosis and rheumatoid arthritis. The three-dimensional structures presented in this review have been published by various research groups and have been deposited in the Protein Data Bank.

article thumbnail

Sygnature Discovery and Daewoong Pharma announce drug discovery research collaboration

Drug Discovery Today

Global integrated drug discovery company, Sygnature Discovery and global healthcare group Daewoong Pharmaceutical, have entered into a research collaboration agreement to accelerate the discovery of a novel small molecule to target autoimmune disease.

article thumbnail

New avenues for rare disease treatment

Drug Target Review

Almost every one of us will know someone with a neurodegenerative disease such as Alzheimer’s or Parkinson’s. It is less common to know someone with a rare genetic disease; but while individually rare, collectively they have an enormous impact. This will, in turn, slow the progression of, or even halt, the disease.

Disease 113
article thumbnail

RNA processing in health and disease: challenges and opportunities of the field

Drug Target Review

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing.

RNA 96
article thumbnail

Condensate biology: advancing drug discovery for complex diseases

Drug Target Review

In recent years, a novel approach known as condensate biology has emerged, revolutionising the way researchers think about drug discovery and development. He now leads research and development (R&D) at Dewpoint. Dewpoint’s breakthrough was the realisation that certain condensates are associated with human diseases.

Disease 98